Takeaways for Immunotherapy Trials in Oncology

Immunotherapy trials in oncology have shown tremendous promise and may represent the most promising cancer treatment approach in the past 50 years.

It’s critical for sponsors and investigators — and everyone else working on your immunotherapy trial – to understand how the immune system responds to cancer treatments. Improper evaluation of response data can signal a lack of efficacy and cause you to prematurely end your trial … when the immunotherapy treatment is actually working.

Here are some key takeaways from our webinar – How Immune-Related Response Criteria Is Changing Immunotherapy Treatments:

  • There is strong evidence that most cancers stimulate the immune system.
  • Efficacy of cancer-induced immunity is limited both by factors secreted by the tumor and stroma and by normal defense mechanisms activated to prevent autoimmunity.
  • Improved understanding of tumor-immune system interactions has led to the design of therapeutic approaches that both stimulate immunity and address mechanisms of immune escape.
  • There are additional logistical and management complexities to address during the planning and conduct phases of the trial compared to a standard oncology trial.
  • There are now several promising immunologic agents that have demonstrated significant anti-tumor efficacy in advanced-stage clinical trials or have been approved for standard-of-care use.

Here is the entire 60-minute webinar:

Here are the webinar slides for download. Feel free to share with your colleagues.

If you have a question about the webinar or your study, submit your question here.

If you think we might be a fit for one of your upcoming immunotherapy trials, let us know your timeframe so we can get it on our schedule. Connect with us or let us know when you submit a question.

Download the Presentation!

This content is designed for CMOs, VPs of Clinical Development, and others designing and managing immunotherapy studies in oncology.